Prognose des europäischen Marktes für Therapeutika gegen Infektionskrankheiten bis 2030 – Regionale Analyse – nach Arzneimittelklasse (antiviral, antibakteriell, antimykotisch und andere), Indikation (HIV, Hepatitis, Tuberkulose, Grippe, HPV und andere), Verabreichungsweg (oral, parenteral, topisch und andere) und Vertriebskanal (Krankenhausapotheken, Einzelhandelsapotheken und andere)
Zunehmender Fokus auf Finanzierung und F&E bei Therapeutika gegen Infektionskrankheiten treibt den europäischen Markt für Therapeutika gegen Infektionskrankheiten an
Forschung und Entwicklung (F&E) ist ein entscheidender Teil des Geschäfts von Biopharmazeutika und Pharmaunternehmen. F&E ermöglicht ihnen, neue Produkte für verschiedene therapeutische Anwendungen mit erheblichem medizinischen und kommerziellen Potenzial auf den Markt zu bringen. Darüber hinaus investieren führende Marktteilnehmer in F&E, um verbesserte Technologien zu entwickeln und mehr Umsatzanteile zu erzielen.
Um Lösungen für die wichtigsten Gesundheitsprobleme zu schaffen, mit denen Europa und der Rest der Welt derzeit konfrontiert sind, investiert die Europäische Union in Forschung, Technologie und Innovation. Die Europäische Kommission hat bei der Förderung der Forschung eine Vorreiterrolle eingenommen, insbesondere im Bereich der Immunität gegen und der Behandlung von Infektionskrankheiten. Zwischen 2007 und 2019 wurden mehr als 4,3 Milliarden US-Dollar (4 Milliarden) für die Erforschung von Infektionskrankheiten bereitgestellt. Darüber hinaus wird Horizont Europa, die kommende (2021-2027) EU-Finanzierungsinitiative für Forschung und Innovation (F&I), weiterhin F&I im Bereich Infektionskrankheiten unterstützen, insbesondere im Zusammenhang mit Armut, vernachlässigten und (wieder)auftretenden Krankheiten.
Horizon Europa ist ein Programm zur Förderung von Forschung und Innovation. Um Barrieren zwischen Regionen zu überwinden und konkrete Kooperationen aufzubauen, legt das Programm großen Wert auf die Sicherstellung der Zusammenarbeit zwischen Universitäten, wissenschaftlichen Gemeinschaften, der Industrie, insbesondere kleinen und mittleren Unternehmen, und Einzelpersonen. Das Gesundheitsarbeitsprogramm skizziert Finanzierungsmöglichkeiten im Rahmen von Horizont Europa für Forschung im Zusammenhang mit Infektionskrankheiten sowie der Vorbereitung und Reaktion auf Pandemien. Der zunehmende Fokus auf F&E und die Finanzierung von Therapeutika für Infektionskrankheiten treibt somit das Wachstum des Marktes für Therapeutika für Infektionskrankheiten voran.
Überblick über den europäischen Markt für Therapeutika gegen Infektionskrankheiten
Der europäische Markt für Therapeutika gegen Infektionskrankheiten ist in Deutschland, Großbritannien, Frankreich, Italien, Spanien und den Rest Europas unterteilt. Europa nimmt auf dem globalen Markt für Therapeutika gegen Infektionskrankheiten eine bedeutende Position ein und wird im Zeitraum 2022–2030 voraussichtlich eine bemerkenswerte CAGR verzeichnen. In der Region gibt es eine erhöhte Inzidenz chronischer Viruserkrankungen und eine hohe Nachfrage nach der Entwicklung neuer antiviraler Medikamente. Mit 15,79 Milliarden US-Dollar, die von 2007 bis 2019 durch das 7. Rahmenprogramm und Horizont 2020 finanziert wurden, und 1,1 Milliarden US-Dollar, die für die COVID-19-Forschung zugesagt wurden, spielt Europa eine entscheidende Rolle bei der Finanzierung und Koordinierung der Forschung zu Infektionskrankheiten. Laut dem Robert Koch-Institut erkranken in Deutschland jedes Jahr etwa 400.000 bis 600.000 Patienten an einer im Krankenhaus erworbenen Infektion, von denen 10.000 bis 15.000 sterben. Typische Probleme für Gesundheitsdienstleister sind Wundinfektionen, Harnwegsinfektionen und Lungenentzündungen. Die Nachfrage nach Antiinfektiva in Deutschland wächst stark, was auf die steigende Zahl geriatrischer Menschen, die zunehmende Verbreitung chronischer Viruserkrankungen und die wachsende Nachfrage nach der Herstellung neuer Moleküle für virale Therapiebereiche zurückzuführen ist, um unerfüllte Probleme zu lösen. Deutschland ist aufgrund der hohen Qualität seiner Fertigprodukte eine der führenden Nationen für die Herstellung antiviraler Mittel und verfügt über Wachstumspotenzial in Europa. So entwickelte beispielsweise das biopharmazeutische Unternehmen Atriva Therapeutics GmbH ATR-002 zur Behandlung von Patienten mit COVID-19 in einer Phase-II-Studie, um die Virusausbreitung von SARS-CoV-2 zu blockieren. Aufgrund der oben genannten Faktoren wird daher erwartet, dass der Markt im Land erheblich wachsen wird.
Umsatz und Prognose des europäischen Marktes für Therapeutika für Infektionskrankheiten bis 2030 (in Mio. USD)
Segmentierung des europäischen Marktes für Therapeutika für Infektionskrankheiten
Der europäische Markt für Therapeutika für Infektionskrankheiten ist nach Arzneimittelklasse, Indikation, Verabreichungsweg, Vertriebskanal und Land kategorisiert.
Basierend auf der Arzneimittelklasse ist der europäische Markt für Therapeutika für Infektionskrankheiten in antivirale, antibakterielle, antimykotische und andere Mittel segmentiert. Das antivirale Segment hatte 2022 den größten Marktanteil.
In Bezug auf die Indikation ist der europäische Markt für Therapeutika für Infektionskrankheiten in HIV, Hepatitis, Tuberkulose, Influenza, HPV und andere segmentiert. HIV hatte 2022 den größten Marktanteil.
Basierend auf dem Verabreichungsweg ist der europäische Markt für Therapeutika für Infektionskrankheiten in oral, parenteral, topisch und andere segmentiert. Das orale Segment hatte 2022 den größten Marktanteil.
In Bezug auf die Vertriebskanäle ist der europäische Markt für Therapeutika für Infektionskrankheiten in Krankenhausapotheken, Einzelhandelsapotheken und andere unterteilt. Die Krankenhausapotheken hatten 2022 den größten Marktanteil.
Nach Ländern ist der europäische Markt für Therapeutika für Infektionskrankheiten in Deutschland, Großbritannien, Frankreich, Italien, Spanien und das übrige Europa unterteilt. Deutschland dominierte 2022 den europäischen Marktanteil für Therapeutika für Infektionskrankheiten.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc und Shionogi & Co Ltd sind einige der führenden Unternehmen auf dem europäischen Markt für Therapeutika für Infektionskrankheiten.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Europe Analysis
5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Infectious Disease Therapeutics Market - Country Analysis
10.1 Europe Infectious Disease Therapeutics Market
10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Europe Infectious Disease Therapeutics Market Segmentation
Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.